Publication Topic

Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr P, Sawyer E, Stephen CD, Eichler F. Healthcare utilization, burden of illness, and mortality in adults with adrenomyeloneuropathy: The case for genetic therapies. Poster presentation, American Society of Cell and Gene Therapy Meeting, Los Angeles, CA, May 2023.

Seo S, Healey B,  McLin R, Sacks N,  Benson C, Citrome L. Health disparities among patients with schizophrenia in an integrated healthcare system. Poster presentation, Psych Congress Elevate 2023, May 30-June 2, 2023.

Jensen I, Srivastava K, Minshall M, Kemp R. Estimating the lifetime burden of illness in patients with bronchiolitis obliterans syndrome. Abstract EE539. ISPOR 2023.

Bean K, Miller B, Jensen I, Fields C, Pang F. Evaluating the face validity of health state utility values (HSUVS) for metachromatic leukodystrophy (MLD). Abstract EE285. ISPOR 2023.

Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr P, Sawyer E, Stephen CD, Eichler F. Substantial burden of illness and mortality in men with adrenomyeloneuropathy. Poster presentation at American Academy of Neurology Annual Meeting, April 2023.

Minshall M, Emden M, McLin R, Kemp P, Pontenani F, Cardosi L, Sacks N. The cost of non-cystic fibrosis bronchiectasis (NCFB) in patients with commercial insurance or Medicare coverage in the US. Poster presentation, ISPOR, April 2023.

Eichler F, Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr P, Sawyer E, Stephen C. The economic impact of adrenomyeloneuropathy (AMN) on direct medical costs in commercially insured US adults: A retrospective study. Poster presentation, ISPOR 27th International Meeting, Boston, MA, April 2023.

Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr P, Sawyer E, Stephen C. Hospitalizations, clinical characteristics and mortality in adults with adrenomyeloneuropathy (AMN): A retrospective study. Poster presentation, ISPOR 27th International Meeting, Boston, MA, April 2023.

Pang F, Dean R, Jensen I, Bean K, Fields C, Miller B. 2023. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US. Mol Gene Metab 138(2):107258; doi: 10.1016/j.ymgme.2022.107258.

Bullano M, Cool C, Schultz BG, Durgapal S, Sacks N, Liu Y, Kee R, Batt K. 2023. Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert Rev Phamacoecon Outcome Res 23(2):225-230; doi: 10.1080/14737167.2023.2160705. PMID: 36537696.

Jensen I, Cyr P. 2022. Early health economic models in gene and cell therapy to inform clinical trial design and optimize commercialization efforts. White Paper. PharmaLive.

Yao W, Jensen I, Claussen M, Dandurand K, Buffington B, Fuentes D, Mikhael M. 2022. Health economics of selective early rescue surfactant administration and standard surfactant administration for newborns with respiratory distress syndrome. J Pediatr Pharmacol Ther 27(8):695–702; doi:  10.5863/1551-6776-27.8.695.

Pang F, Dean R, Jensen I, Tehard B, Roze S, Olaye A, et al. The cost-effectiveness of atidarsagene autotemcel for the treatment of metachromatic leukodystrophy (MLD) in France. Abstract EE24. ISPOR 2022.

Habib A, Sacks NC, Cool C, Durgapal S, Hughes T, Hernandez J, Phillips G. Trends in hospital admissions and readmissions for patients with MG from U.S. national research databases. Poster presentation, American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting, September 2022.

Sacks NC. Healthcare resource utilization in non-cystic fibrosis bronchiectasis (NCFB) patients with commercial insurance coverage in the US. Poster presentation, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)Europe, November 2022.

Jensen IS, Wu E, Cyr PL, Claussen M, Winkler T, Salahuddin K, Prats J, et al. 2022. Cost-consequence analysis of using cangrelor in high angiographic risk percutaneous coronary intervention patients: A US hospital perspective. Am J Cardiovasc Drugs 22(1):93-104; doi: 10.1007/s40256-021-00491-9. PMID: 34331235.

Alexander AW, Jensen IJ, Hathaway J, Srivastava K, Cyr PL, Sidonio RF, Batt K. 2022. Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements. J Manag Care Spec Pharm 28(5):518-527; doi: 10.18553/jmcp.2022.21197. PMID: 35343812.

Sacks NC, Healey BE, Raza S, Cyr PL, Boerner G, Sheshadri A. 2022. The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States. Blood Adv 6(5):1566–1576; doi: 10.1182/bloodadvances.2021004364. PMID: 34807973.

Sheshadri A, Sacks NC, Healey B, Cyr P, Boerner G, Huang HJ. 2022. The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States. J Med Econ 25(1):650–659; doi: 10.1080/13696998.2022.2071065. PMID: 35502563.